Actinogen gets upbeat results from Xanamem trial for Alzheimer’s treatment

April 27, 2022 07:28 PM AEST | By Aditi Sarkar
Follow us on Google News:

Highlights

  • Actinogen Medical receives encouraging results for XanaMIA Part A trial for its lead compound Xanamem
  • The results confirm the potential of Xanamem to improve cognition even in a cognitively normal population
  • Xanamem exhibited a good safety profile and a full pharmacodynamic activity in the trial
  • The company is planning a part B trial to study the effects of Xanamem in patients at the early stages of the disease

Biotechnology company Actinogen Medical (ACW) has struck another landmark in the development of a new treatment for Alzheimer’s disease. The firm has got positive XanaMIA Part A trial results for its lead compound Xanamem®, which is currently being developed as a promising new therapy for Alzheimer’s disease, Fragile X Syndrome, Depression, and other neurological diseases.

The positive results from the trial confirm the potential of Xanamem to improve cognition even in a cognitively normal population. 5 mg and 10 mg daily doses of Xanamem exhibited a good safety profile and a full pharmacodynamic activity supportive of continued development.

Related read: ACW, IHL & CGS: ASX healthcare penny stocks with over 150% returns in one year 

According to Professor Paul Rolan, Actinogen’s Chief Medical Officer, the results validate the positive effects of Xanamem on cognition, with outstanding safety. They significantly boost the Alzheimer’s Disease program and open the door to Xanamem’s assessment of other chronic neurological and psychiatric diseases where poor cognition is a significant complaint.

What next?

Detailed results of the trial will be reviewed with experts from academics and industry for finalising the following Alzheimer’s Disease program trial. The company is planning a part B trial to study the effects of Xanamem in patients at the early stages of the disease. The trial design will be broadly like the Part A trial. 

Also read: Updates from ASX healthcare penny stocks: ACW, EMD, AGN and M7T 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.



Top ASX Listed Companies

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK